Arcus Biosciences Inc (RCUS)
16.65
+1.34
(+8.75%)
USD |
NYSE |
Oct 04, 16:00
16.66
+0.01
(+0.06%)
After-Hours: 20:00
Arcus Biosciences Shareholders Equity (Annual): 462.00M for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 462.00M |
| December 31, 2022 | 657.00M |
| December 31, 2021 | 842.00M |
| December 31, 2020 | 502.30M |
| Date | Value |
|---|---|
| December 31, 2019 | 163.84M |
| December 31, 2018 | 234.94M |
| December 31, 2017 | 153.87M |
| December 31, 2016 | 99.46M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
163.84M
Minimum
2019
842.00M
Maximum
2021
525.43M
Average
502.30M
Median
2020
Shareholders Equity (Annual) Benchmarks
| Merck & Co Inc | 37.58B |
| Trevena Inc | -7.657M |
| Syndax Pharmaceuticals Inc | 554.20M |
| Clearside Biomedical Inc | -15.91M |
| Janux Therapeutics Inc | 344.35M |